Published summary: 2026-03-07
Where the evidence converges
First meta-analysis of cannabis withdrawal prevalence: 47% of regular/dependent users experienced clinically significant withdrawal across 23 studies and 27,000+ participants
Strong evidence · 11 studies
High heterogeneity across studies (I² values) reflects differences in withdrawal definitions, assessment tools, and study populations. Most participants were from clinical or treatment-seeking samples
Meta-analysis of 4 RCTs found cannabis users with PTSD still benefited from trauma-focused therapy, but attended fewer sessions and showed less improvement in other substance use
Strong evidence · 11 studies
Only 4 of 36 Project Harmony trials included — those that assessed cannabis use at baseline. The 33.2% cannabis use rate may not reflect current patterns (cannabis use has increased since some trials
Analysis of 920 participants found reducing cannabis use ~50% in frequency and ~75% in amount was associated with clinician-assessed improvement
Strong evidence · 11 studies
Exploratory, not pre-specified. CART accuracy varied (40-75%). Aggregated data from different designs. Correlation not causation.
Where questions remain
Among 1,481 heavy smokers trying to quit with nicotine patches, marijuana users had half the odds of success
Moderate evidence · 41 studies
Marijuana use was self-reported and not the primary study outcome. The study did not control for the type, frequency, or quantity of marijuana use. It cannot determine whether marijuana use causally i
Among 75 marijuana users who lapsed after treatment, those who blamed themselves and saw the cause as permanent and pervasive were more likely to return to regular use over six months
Moderate evidence · 41 studies
Relatively small sample. The assessment of attributions at the time of lapse may have been influenced by current use status. The study cannot determine whether attributions caused relapse or whether i
Self-efficacy for avoiding marijuana predicted frequency of post-treatment use better than complete abstinence
Moderate evidence · 41 studies
Self-efficacy was self-reported and may reflect optimism rather than actual capability. The relapse prevention treatment produced only marginally greater self-efficacy. The study could not determine w
In 199 smokers trying to quit, alcohol use predicted failure at all follow-up points
Moderate evidence · 41 studies
Relatively small sample (199). Marijuana use was self-reported and the 21% rate may reflect varying use levels. The study may not have been powered to detect smaller marijuana effects. The clinic popu
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Cannabis Use Makes Quitting Tobacco Harder, But CBD Might Help
With 18-22% of tobacco users also using cannabis, understanding how co-use affects quit attempts is critical. The key distinction here is that casual cannabis use hurts cessation, but pharmacologically targeted CBD could actually help.
CBT with Motivational Enhancement Is the Best-Supported Psychotherapy for Cannabis Use Disorder
With no approved medications for CUD, psychosocial interventions are the primary treatment option. This meta-analysis identifies MET-CBT as the most evidence-supported approach while highlighting an important tension: the most effective therapy also had the highest dropout rate.
Cannabis Users with PTSD Still Benefit from Trauma-Focused Therapy — But Attend Fewer Sessions
Clinicians have been uncertain whether to proceed with trauma-focused therapy for PTSD patients who use cannabis. This analysis says: yes, proceed — the therapy still works. But expect lower attendance and be aware that cannabis users may not reduce other substance use as much. This shifts the clini
Reducing Cannabis Use by 50-75% Was Enough to See Real Improvements
This provides data-driven evidence that significant reduction without complete abstinence produces meaningful clinical improvement.
About Half of Heavy Cannabis Users Experience Withdrawal. This Meta-Analysis Measured It.
For years, cannabis withdrawal was dismissed or minimized — both in popular culture and in clinical settings. This meta-analysis put a hard number on it: 47%. That's not everyone, but it's not a small minority either. Roughly half of heavy users will experience a clinically recognizable withdrawal s
Varenicline reduced cannabis use in men with cannabis use disorder but not in women
There are no FDA-approved medications for cannabis use disorder. This trial adds to a small but growing body of evidence that biological sex may determine which pharmacological treatments work, a finding that could reshape how CUD medications are developed and tested.
How the research developed
Pre-2000
7 studies published. Predominantly observational and review studies.
2000–2009
8 studies published. Includes 2 RCTs.
2010–2014
42 studies published. Includes 11 RCTs, 2 strong-evidence studies.
2015–2019
48 studies published. Includes 13 RCTs, 5 strong-evidence studies.
2020–present
116 studies published. Includes 5 meta-analyses, 33 RCTs, 18 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 221 peer-reviewed studies: 5 meta-analyses (2%), 59 randomized controlled trials (27%), 43 observational studies (19%), 25 reviews (11%), 6 case studies (3%), 83 other study types (38%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.